版本:
中国

BRIEF-ArQule receives clearance of IND application from the FDA for proprietary reversible BTK inhibitor, ARQ 531

April 11 ArQule Inc

* ArQule receives clearance of investigational new drug application from the FDA for proprietary reversible BTK inhibitor, ARQ 531

* ArQule Inc - ArQule plans to initiate a phase 1A/B dose escalation and signal generation trial by Q3 of 2017

* ArQule - Upon completion of phase 1a trial, plans to begin phase 1B trial in number of expansion cohorts

* ArQule Inc - Expansion cohorts will include patients with C481S mutation who are refractory to other therapies Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐